Femasys Inc (FEMY)
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Last price
- $1.41
- As of
Kresmion compiles this page from FEMY's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
FEMASYS INC (FEMY): 1 institutional manager tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-08-14.
See the full FEMY dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for FEMY on one page. Preview it with sample data, then open it live with a free account.
Preview the FEMY dossierActive events for FEMY
- mediumEarnings below estimates
Q2-2026: Missed consensus by 16.9%, EPS $-1.55 vs $-1.326 estimate
- medium13F: new position
CITADEL ADVISORS LLC new position in FEMY
- mediumEarnings above estimates
Q2-2025: Beat consensus by 18.3% - EPS $-3 vs $-3.672 estimate
- mediumEarnings above estimates
Q3-2025: Beat consensus by 24.6% - EPS $-2 vs $-2.652 estimate
- mediumEarnings above estimates
Q4-2025: Beat consensus by 88.8% - EPS $-0.2 vs $-1.785 estimate
FREE, NO ACCOUNT
Every event on FEMY, as it fires
You are seeing 5 of 10 events recorded on FEMY since 2026-06-10.
The five above landed across 3 days. The other 5 were recorded on 1 other days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in FEMY (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| CITADEL ADVISORS LLCCUSIP 31447E204 · 2026Q2 | $71K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, FEMY
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
FEMY against its peers
FEMY's operating margin of -767.0% ranks in the 22nd percentile of 15 Medical Instruments & Supplies sub-industry peers, fiscal periods ending between 2025-09-30 and 2026-06-30.
| Metric | FEMY | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 2.3M USD | 20.7M USD | 16 | 15 |
| Revenue YoY | n/a | 35.4% | n/a | 6 |
| Gross margin | 62.0% | 52.7% | 66 | 15 |
| Operating margin | -767.0% | -55.3% | 22 | 15 |
| Net margin | -812.3% | -48.3% | 21 | 16 |
| Return on equity | -317.4% | -63.3% | 13 | 18 |
Peers (20): BNGO, CUPR, RVP, UEEC, RGNT, LUCY, MLSS, MHUAF, HBIO, NEPH, POCI, MBOT, NXGL, GCTK, NYXH, YBGJ, STXS, KRMD, ZJYL, NNNN. Left out: RSCF (period gap), ZTEKF (no annual filing), DXR (no annual filing), TUTH (no annual filing), DAVI (no annual filing). Fiscal periods ending between 2025-09-30 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (FEMY: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow FEMY on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to FEMY for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.